CLRB — Cellectar Biosciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-03-07.
Performance
Technicals
Others in Healthcare
Measured signals that fired on CLRB
| date | signal | measured base rate |
|---|---|---|
| 2026-06-12 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-05-07 | CARUSO JAMES V Chief Executive Officer | Open-market purchase | 8.7K | 2.88 | 25.0K |
| 2026-05-07 | Longcor Jarrod Chief Operating Officer | Open-market purchase | 8.7K | 2.88 | 25.0K |
| 2025-12-12 | NEIS JOHN Director | Open-market sale | 198 | 3.70 | 733 |
| 2025-07-02 | Longcor Jarrod Chief Operating Officer | Open-market purchase | 10.0K | 4.99 | 49.9K |
| 2025-07-02 | CARUSO JAMES V Chief Executive Officer | Open-market purchase | 10.0K | 4.99 | 49.9K |
| 2025-07-02 | Kolean Chad J Chief Financial Officer | Open-market purchase | 5.0K | 4.99 | 24.9K |
| 2025-01-10 | Longcor Jarrod Chief Operating Officer | Open-market purchase | 30.0K | 0.28 | 8.4K |
| 2023-12-08 | Longcor Jarrod Chief Operating Officer | Grant or award | 42.9K | 0.00 | 0 |
| 2023-12-08 | Shustov Andrei Senior Vice President, Medical | Grant or award | 47.9K | 0.00 | 0 |
| 2023-12-08 | Kolean Chad J Chief Financial Officer | Grant or award | 42.6K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| Bleichroeder LP | 254.0K | 100.0K |
| VANGUARD CAPITAL MANAGEMENT LLC | 208.0K | 81.9K |
| GEODE CAPITAL MANAGEMENT, LLC | 134.1K | 52.8K |
| Riverview Capital Advisers, LLC | 50.1K | 10.4K |
| Sequoia Financial Advisors, LLC | 47.9K | 18.9K |
| VANGUARD FIDUCIARY TRUST CO | 42.1K | 16.6K |
| Warberg Asset Management LLC | 35.3K | 13.9K |
| UBS Group AG | 24.5K | 9.6K |
| BlackRock, Inc. | 12.1K | 4.7K |
| Tower Research Capital LLC (TRC) | 2.0K | 793 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-13 | — | on EDGAR ↗ |
| 8-K | 2026-08-13 | 2026-08-13 | on EDGAR ↗ |
| 10-Q | 2026-08-13 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-04 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Cellectar Biosciences, Inc. (CLRB) filed form 8-K · 2026-08-13 · SEC EDGAR
- Cellectar Biosciences GAAP EPS of -$0.57 misses by $0.05 · 2026-08-13
- Cellectar Biosciences Q2 2026 Earnings Preview · 2026-08-12
Ask the AI about CLRB
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →